Back to homepage

Women’s health

Experience with ospemifene in patients with vulvar and vaginal atrophy and a history of breast cancer: case studies

Authors: Mariella Lilue MD, Santiago Palacios MD, PhD, María del Carmen Pingarrón Santofimia MD

Women with breast cancer are at a higher risk of developing vulvar and vaginal atrophy (VVA). Ospemifene is approved to treat VVA in postmenopausal women with a history of breast cancer after completion of all breast cancer (including adjuvant) treatments. This article examines the background characteristics and outcomes in two postmenopausal women with a history of breast cancer who were treated with ospemifene for VVA.

More

Experience with ospemifene in patients with vulvar and vaginal atrophy: case studies with bone marker profiles

Authors: María del Carmen Pingarrón Santofimia MD, Silvia Pilar González Rodríguez MD, PhD, Mariella Lilue MD, Santiago Palacios MD, PhD

In this case report, outcomes in relation to bone homeostasis, bone mineral density (BMD), and osteopenia– osteoporosis are examined in postmenopausal women during treatment with ospemifene for vulvar and vaginal atrophy (VVA), a component of the genitourinary syndrome of menopause.

More

Ospemifene for vulvar and vaginal atrophy: an overview

Authors: Santiago Palacios MD, PhD

This editorial article introduces a Special Focus Issue entitled “Treatment of Vulvar and Vaginal Atrophy: Clinical Experience with Ospemifene”. Ospemifene is a selective estrogen receptor modulator indicated for treatment of moderate-to-severe symptomatic vulvar and vaginal atrophy in postmenopausal women who are not candidates for local vaginal estrogen therapy or have contraindications for estrogen products.

More

Clinical study of the tolerability of calcium carbonate–casein microcapsules as a dietary supplement in a group of postmenopausal women

Authors: Santiago Palacios PhD, MD, Marieta Ramirez MD, Mariella Lilue MD

This article reviews the tolerability of a new delivery system for calcium supplementation, based on the functionalization of calcium carbonate (CaCO3) particles by casein proteins, in a randomized, prospective, double-blind, active comparator clinical trial.

More

Management of psoriasis in pregnancy – a review of the evidence to date

Authors: Clara Ferreira MD, Alexandra Azevedo MD, Miguel Nogueira MD, Tiago Torres MD, PhD

This article reviews the impact of psoriasis during pregnancy, how the disease can be managed pharmacologically during this period according to the available armamentarium, and the possible effects of the therapeutic options for the mother and the foetus.

More